Introduction
============

Ovarian cancer is the fifth leading cause of cancer-related deaths in women. According to the GLOBOCAN 2012 database, the incidences of ovarian cancer are 9.1 per 1,00,100 in developed countries and 5.0 per 1,00,000 in developing countries.[@b1-cmar-10-3033] There-into, approximately 70% is high-grade serous carcinomas.[@b2-cmar-10-3033] Up to now, despite the effective treatments including radical resection, systemic chemotherapy, and targeted drugs for patients, the average 5-year survival is still only at 46%.[@b3-cmar-10-3033] Ovarian cancer is a multifactorial disease caused by the interaction of genetic and epigenetic factors.[@b4-cmar-10-3033],[@b5-cmar-10-3033] (TSGs). Hypermethylation in the proximal promoter region often contributes to the transcriptional downregulation but methylation in exons is associated with active transcription.[@b6-cmar-10-3033],[@b7-cmar-10-3033] Recently, mounting evidences demonstrated that DNA methylation was involved in ovarian cancer.[@b8-cmar-10-3033]--[@b10-cmar-10-3033] Therefore, identifying the role of TSG methylation in patients with ovarian cancer is of value.

*P16^INK4a^* (also known as *CDKN2A*), a classical TSG, is located on chromosome 9p21 and plays an important role in cell cycle regulation by decelerating cells progression from G1 to S phase.[@b11-cmar-10-3033],[@b12-cmar-10-3033] It has become clear that the expression of *P16* is reduced by DNA methylation.[@b13-cmar-10-3033]--[@b15-cmar-10-3033] Also, *P16^INK4a^* inactivation upregulates retinoblastoma (RB) protein by stimulating the cyclin-dependent kinases (CDKs) and RB pathway, which leads to dysfunction of cell proliferation and apoptosis, thereby further facilitating carcinogenesis.[@b16-cmar-10-3033] Indeed, several types of cancer, including ovarian cancer, exhibit a methylation phenotype of *P16^INK4a^*.[@b17-cmar-10-3033]--[@b19-cmar-10-3033]

To date, even though abundant studies have been conducted to explore the role of *P16^INK4a^* promoter methylation in ovarian cancer, the results are still inconclusive. Several studies reported that *P16^INK4a^* promoter methylation was associated with an increasing trend in ovarian cancer,[@b20-cmar-10-3033]--[@b23-cmar-10-3033] while, other studies suggested that *P16^INK4a^* promoter methylation was not related to the occurrence of ovarian cancer.[@b24-cmar-10-3033]--[@b30-cmar-10-3033] Interestingly, even the conclusions in two published meta-analyses were inconsistent. Xiao et al reported that aberrant methylation of *P16^INK4a^* was significantly associated with ovarian carcinogenesis,[@b31-cmar-10-3033] while Jiang et al suggested no association between *P16^INK4a^* methylation and epithelial ovarian cancer.[@b32-cmar-10-3033]

Considering these conflicting conclusions on the role of methylated *P16^INK4a^* in ovarian cancer, we performed an adaptive synthesized analysis to quantitatively evaluate the occurrence frequency, clinicopathological features, and potential prognostic significance of *P16^INK4a^* promoter methylation in ovarian cancer. Moreover, we searched The Cancer Genome Atlas (TCGA) database, collecting hundreds of ovarian cancer samples with whole genome DNA methylation datasets to validate our meta-analysis.

Materials and methods
=====================

Search strategy and selection criteria
--------------------------------------

PubMed, Embase, Web of Science, and China National Knowledge Infrastructure were searched up to April 12, 2017, by the following keywords and search items: (*P16* OR *P16^INK4a^* OR *CDKN2A*) AND (methylation OR hypermethylation OR demethylation) AND (ovarian OR ovary) AND (cancer OR carcinoma OR neoplasm). The search was limited to human studies, without language restriction. Moreover, a manual search of the relevant references was implemented to identify the potentially additional articles.

The following criteria were used for screening eligible studies: 1) case--control studies evaluating the association between *P16^INK4a^* promoter methylation and ovarian cancer risk, or case only studies evaluating the association of *P16^INK4a^* promoter methylation with clinicopathological features or prognosis in ovarian cancer; 2) articles providing sufficient information for calculating an odds ratio (OR) and corresponding 95% CI, or study offering hazard ratio (HR) and 95% CI directly; 3) sample types limited to tissues; and 4) studies with full-text articles. It is worth noting that when multiple reports were published from a same study population, only the most recent or complete information was included in this meta-analysis. Meanwhile, studies with Newcastle Ottawa Scale (NOS) scores greater than or equal to five were enrolled.

Data extraction and quality assessment
--------------------------------------

With a preformed unified form, data were extracted independently by two investigators, and disagreements were resolved by discussion till consensus was achieved. The following information was extracted from studies: the first author's name, publication year, country, geographical location, sample size, age of patients in the case group, the frequencies of methylation in the case and control groups, methods for detecting methylation, methylation site, disease stage, tumor grade, histological subtype, and effects on survival outcomes.

The quality of eligible case--control studies was assessed according to the NOS criteria.[@b33-cmar-10-3033] The NOS criteria are based on three aspects: 1) subject selection: 0--4; 2) comparability of subject: 0--2; 3) clinical outcome: 0--3.

Statistical analysis
--------------------

Statistical analysis was conducted with Review Manager 5.2 (Cochrane Collaboration, Oxford, UK) and the Stata 12.0 (Stata Corporation, College Station, TX, USA). ORs with corresponding 95% CIs were calculated to estimate the association between *P16^INK4a^* promoter methylation and ovarian cancer risk or clinicopathological features. Meanwhile, HRs and 95% CIs were used to assess the prognosis of *P16^INK4a^* promoter methylation on ovarian cancer. Inter-study heterogeneity was estimated with the Cochran's *Q* statistic and *I*^2^ tests. *P*\<0.05 or *I*^2^\>50% indicated substantial heterogeneity, and then the random-effects model was applied. Otherwise, the fixed-effects model was selected. We also explored sources of heterogeneity using meta-regression and subgroup analyses by publication year, geographical location, method, and case sample size. Additionally, sensitivity analysis was performed to investigate the influence of individual study. Publication bias was evaluated by funnel plots and Begg's test, and *P*\<0.05 was considered statistically significant. It is worth mentioning that, for some trials containing no events in both case and control arms, as no information supplied about the likely magnitude of the effect, we excluded such trials when synthesizing data.[@b34-cmar-10-3033]

TCGA datasets extraction and analysis
-------------------------------------

We collected DNA methylation datasets of 582 ovarian cancer cases and 12 ovarian normal tissues from TCGA ("TCGA-ovary \[OV\]" project) program.[@b35-cmar-10-3033] The methylation measurement was performed using Illumina HumanMethylation27 BeadChip. Beta value of each CpG site was extracted to assess the methylation level of *CDKN2A* gene. Beta value was calculated based on the intensities of the methylated (M) and unmethylated (U) bead types: beta value = M/(M+U).[@b36-cmar-10-3033] The difference of DNA methylation level of CpG sites between ovarian tumor tissues and normal ovarian tissues in TCGA database was analyzed by Student's *t*-test on the means. *P16^INK4a^* gene expression value (fragments per kilobase of transcript per million mapped reads) in ovarian tumor tissues (TCGA, "TCGA-OV" project) was also extracted. Pearson's product-moment correlation between *P16^INK4a^* gene expression levels and methylation of its CpG islands was evaluated. Data analysis was performed using R software (R i386 3.4.0). *P*-values were adjusted via Bonferroni correction.

Results
=======

Identification of relevant studies
----------------------------------

The procedure of study selection is outlined in [Figure 1](#f1-cmar-10-3033){ref-type="fig"}. We identified 233 articles in the initial literature search. A total of 153 references remained after removing duplicates. After reading titles and abstracts, 84 records were identified for further full-text assessment, which further excluded 60 more articles. Finally, 24 studies from 1997 to 2015 were included in this meta-analysis.[@b17-cmar-10-3033],[@b20-cmar-10-3033],[@b22-cmar-10-3033]--[@b30-cmar-10-3033],[@b37-cmar-10-3033]--[@b49-cmar-10-3033]

Baseline characteristics of included studies
--------------------------------------------

Out of the 24 studies, 11 studies were conducted in Asia, 7 in Europe, 4 in America, 1 in Africa, and 1 in Oceania. The detection methods of methylation in 20 studies were methylation-specific PCR (MSP) and real-time quantitative MSP, while methylation-specific multiplex ligation-dependent probe amplification was used in two studies, MethyLight was used in one study, and Southern analysis was used in one study. Among the 24 articles, 20 studies[@b17-cmar-10-3033],[@b20-cmar-10-3033],[@b22-cmar-10-3033]--[@b30-cmar-10-3033],[@b37-cmar-10-3033]--[@b40-cmar-10-3033],[@b42-cmar-10-3033],[@b45-cmar-10-3033]--[@b47-cmar-10-3033],[@b49-cmar-10-3033] addressed the risk of *P16^INK4a^* promoter methylation in ovarian cancer, 10 studies[@b20-cmar-10-3033],[@b25-cmar-10-3033],[@b28-cmar-10-3033],[@b29-cmar-10-3033],[@b38-cmar-10-3033],[@b41-cmar-10-3033],[@b43-cmar-10-3033],[@b44-cmar-10-3033],[@b47-cmar-10-3033],[@b48-cmar-10-3033] covered clinicopathological features, and 3 studies[@b20-cmar-10-3033],[@b42-cmar-10-3033],[@b43-cmar-10-3033] discussed prognosis. To explore the relationship between *P16^INK4a^* promoter methylation and ovarian cancer risk, three groups, that is, normal tissues, benign tissues, and low malignant potential or borderline tumor tissues (LMP), were compared. The NOS scores of all case--control studies were ≥5. The basic characteristics of all included studies are summarized in [Tables 1](#t1-cmar-10-3033){ref-type="table"} and [2](#t2-cmar-10-3033){ref-type="table"}.

Quantitative data synthesis
---------------------------

### Association between *P16INK4a* promoter methylation and ovarian cancer risk

A total of 1,217 ovarian cancers, 116 LMP cancers, 271 benign patients, and 351 normal controls were quantitatively synthesized in this analysis. Results indicated that the frequency of *P16^INK4a^* promoter methylation in cancer tissues was significantly elevated than that in normal tissues (OR=5.01, 95% CI=1.55--16.14) and LMP tissues (OR =1.88, 95% CI=1.10--3.19), but similar to benign tissues (OR =1.18, 95% CI=0.52--2.65; [Figure 2](#f2-cmar-10-3033){ref-type="fig"}). Further analyses showed that the frequencies of *P16^INK4a^* promoter methylation in benign tissues and LMP tissues were not higher than those in normal tissues (OR =2.28, 95% CI=0.37--14.09; OR =2.28, 95%CI=0.15--34.73, respectively; [Figure 3](#f3-cmar-10-3033){ref-type="fig"}).

With large heterogeneity, meta-regression and subgroup analyses were conducted by the publication year, geographical location, method, and case sample size in the comparison of cancer tissues vs normal tissues. Meta-regression found that case sample size was significantly correlated with the inter-study heterogeneity (*P*=0.041) while other covariates were not ([Table 3](#t3-cmar-10-3033){ref-type="table"}). Furthermore, as shown in [Table 3](#t3-cmar-10-3033){ref-type="table"}, subgroup analyses revealed that the OR was 5.69 (95% CI=0.42--76.14) for the publication year ≤2005 and 4.71 (95% CI=1.30--17.07) for \>2005 under the random-effects model. For geographical location, the OR was 7.85 (95% CI=1.33--46.32) in Asia, 2.31 (95% CI=0.24--22.01) in America, and 6.10 (95% CI=1.89--19.69) in Africa under random-effects model. For test method, the OR for MSP was 4.49 (95% CI=0.97--20.64) under random-effects model and 8.11 (95% CI=2.93--22.40) for other methods under fixed-effects model. In addition, the OR was 15.75 (95% CI=4.05--61.34) for sample size \<50 in fixed-effects model and 2.21 (95% CI=1.33--3.67) for that ≥50 in random-effects model.

### Association between *P16^INK4a^* promoter methylation and clinicopathological features in patients with ovarian cancer

Ten studies comprising 680 samples were enrolled to assess whether or not the abnormal *P16^INK4a^* promoter methylation was associated with ovarian cancer clinicopathological characteristics. As displayed in [Figure 4](#f4-cmar-10-3033){ref-type="fig"}, no statistically significant correlation was found between *P16^INK4a^* promoter methylation and age of patients (≥60 vs\<60: OR =1.39, 95% CI=0.66--2.92), clinical stage (III--IV vs I--II: OR =1.21, 95% CI=0.81--1.82), grade (3 vs 1--2: OR=1.20, 95% CI=0.82--1.1.75) as well as histological subtype (serous vs non-serous: OR=1.09, 95% CI=0.76--1.55).

### Prognostic value of *P16^INK4a^* promoter methylation in patients with ovarian cancer

Only two studies[@b42-cmar-10-3033],[@b43-cmar-10-3033] containing 464 patients evaluated the *P16^INK4a^* promoter methylation on progression-free survival (PFS) and three studies[@b20-cmar-10-3033],[@b42-cmar-10-3033],[@b43-cmar-10-3033] containing 600 patients on overall survival (OS). The combined results revealed *P16^INK4a^* promoter methylation was significantly associated with a poor PFS by univariate Cox proportional hazards regression model (HR=1.68, 95% CI=1.26--2.24; [Figure 5A](#f5-cmar-10-3033){ref-type="fig"}). After considering potential confounders by adjusting for age at diagnosis or surgery, disease stage, histological grade, and residual tumor size, the pooled HR was 1.55 (1.15--2.08; [Figure 5B](#f5-cmar-10-3033){ref-type="fig"}). Survival analysis also showed that *P16^INK4a^* promoter methylation reduced OS in univariate and multivariate Cox regression models (HR =1.28, 95% CI=0.97--1.68; HR =1.16, 95% CI=0.87--1.55, respectively; [Figure 5C and D](#f5-cmar-10-3033){ref-type="fig"}), but the differences were not statistically significant.

### Sensitivity analysis and publication bias

As presented in [Figure 6A--C](#f6-cmar-10-3033){ref-type="fig"}, no single study significantly affected the pooled ORs in the sensitivity analysis, indicating our analysis was relatively stable and credible. Funnel plots and Begg's test were used to evaluate the publication bias. The funnel plots were largely symmetric suggesting there were no publication biases in the meta-analysis of *P16^INK4a^* promoter methylation and ovarian cancer risk, which was confirmed by the Begg's test ([Figure 6D--F](#f6-cmar-10-3033){ref-type="fig"}).

### Methylation level of *P16^INK4a^* measured by TCGA program

To further explore the methylation level of *P16^INK4a^* in ovarian tumor tissues, we extracted DNA methylation data of *P16^INK4a^* CpG sites measured with Illumina HumanMethylation27 BeadChip from TCGA program. As shown in [Table 4](#t4-cmar-10-3033){ref-type="table"}, the beta values of 582 ovarian tumor tissues and 12 normal ovarian tissues were extracted for analysis. Obviously, the methylation levels of seven out of nine CpG sites were significantly increased in the ovarian tumor tissues compared with the normal tissues (cg03079681, cg07752420, cg09099744, cg10895543, cg11653709, cg12840719, and cg26673943). Among these regions, methylation level of probe cg26673943 region (located at the promoter region of *P16^INK4a^*) was negatively associated with *P16^INK4a^* expression in ovarian cancer patients (adjusted *P*-value \<0.000001). However, methylation levels of the rest six probes, which are located at non-promoter region tended to be positively associated with *P16^INK4a^* gene expression. Additionally, we found that methylation level of probe cg13479669 region was lower in tumor tissues compared with normal tissues, and negatively associated with *P16^INK4a^* gene expression in tumor tissues. These results suggest that hypermethylation of *P16^INK4a^* might be correlated with ovarian carcinogenesis and development. Nevertheless, it seems that the methylation at promoter region or non-promoter region has contrary effects on *P16^INK4a^* gene expression.

Discussion
==========

Ovarian cancer is one of the leading causes of cancer-related deaths in women.[@b50-cmar-10-3033] Identification of early disease indicators for diagnosis and prognosis is of clinical value. *P16^INK4a^*, which resembles classic TSGs such as *P53*, is an important negative regulator of cell growth and proliferation.[@b16-cmar-10-3033] It has been synthetically evaluated for aberrant *P16^INK4a^* methylation in numerous cancers,[@b51-cmar-10-3033]--[@b54-cmar-10-3033] including ovarian cancer.[@b31-cmar-10-3033],[@b32-cmar-10-3033] Considering the conflicting conclusions in two meta-analyses and the lack of comprehensive assessment on the role of methylated *P16^INK4a^* in ovarian cancer, we performed an adaptive synthesized analysis to investigate the relationships between *P16^INK4a^* promoter methylation and ovarian cancer risk, as well as clinicopathological features and prognostic value in ovarian cancer. Meanwhile, we searched TCGA data to validate our meta-analysis.

Our meta-analysis demonstrated that *P16^INK4a^* promoter methylation in cancer tissues was significantly higher than that in normal tissues (*P*\<0.05), but not much increased than that in benign tissues. Compared with normal tissues, the frequency of *P16^INK4a^* promoter methylation was 2.28-fold higher in both benign tissues and LMP tissues (*P*\>0.05), but the differences were not statistically significant. The reason for this phenomenon may be that the transformation of normal cells to cancer cells is a long-term, gradual, and multiphase process.[@b55-cmar-10-3033] Although not establishing a strong correlation between *P16^INK4a^* promoter methylation and cancer progression, the above results do suggest a possibility that epigenetic alteration of *P16^INK4a^* promoter methylation might play a certain role in ovarian carcinogenesis and might be useful in distinguishing malignant tumor from healthy ovarian tissues. Considering the evident heterogeneity, we conducted subgroup analyses based on probable covariates in the comparison of cancer tissues vs normal tissues. For geographical location, *P16^INK4a^* promoter methylation is a risk factor in Asia and Africa, but not in America. The divergence may be underscored in a large part to a combination of differences in allele frequencies and complex epistasis or gene--environment interactions.[@b56-cmar-10-3033] A review also outlined that some factors such as distinct physical appearance, behavior, and response to environ mental agents and drugs between human populations could have contributed to the epigenetic variations.[@b57-cmar-10-3033] Similar findings appeared in the subgroup analyses of different methods and publication year. Kurdyukov and Bullock[@b58-cmar-10-3033] suggested that it was essential to choose an appropriate method in a suitable region to answer a particular biological question in studies of DNA methylation. Additionally, the 95% CI was large in the group of small sample size while relatively small in the group of large sample size, implying the conclusion may not be reliable unless studies should be conducted using a sufficient number of samples. Previous studies also demonstrated that the methylation status in blood samples or fluids might be different from that in tissues.[@b59-cmar-10-3033],[@b60-cmar-10-3033] Thus, our results should be interpreted with caution because sample types were limited to tissues in studies included in this meta-analysis.

Previous studies indicated that *P16^INK4a^* promoter methylation was associated with poorly differentiated tumors and was different in histological subtype in ovarian cancer.[@b22-cmar-10-3033],[@b43-cmar-10-3033] However, we could not establish any significant correlations between *P16^INK4a^* promoter methylation and clinicopathological features, including age, clinical stage, tumor differentiation or histological subtype in this study. Therefore, it might not be essential to predict the invasion and metastasis of ovarian cancer.

Katsaros et al[@b43-cmar-10-3033] and Wiley et al[@b42-cmar-10-3033] reported association of *P16^INK4a^* promoter methylation with PFS and OS in ovarian cancer, while Bhagat et al[@b20-cmar-10-3033] found no significant value in predicting prognosis. In the present study, we discovered that *P16^INK4a^* promoter methylation represented a risk factor for PFS. For OS, patients with *P16^INK4a^* promoter methylation also had a slightly elevated risk, though the differences are not statistically significant. This trend was also observed in other types of cancer.[@b51-cmar-10-3033],[@b54-cmar-10-3033] However, its statistical confirmation requires large studies. The data from TCGA also indicated that methylation level of probe cg26673943 region (located at the promoter region of *P16^INK4a^*) in the ovarian tumor tissues was higher than normal ovarian tissues. Increased methylation of CpG island at the promoter region was negatively associated with *P16^INK4a^* gene expression, while methylation of CpG islands at non-promoter regions was positively associated with *P16^INK4a^* expression.

Compared with previous meta-analyses,[@b31-cmar-10-3033],[@b32-cmar-10-3033] our meta-analysis had several improvements. First, the development of ovarian cancer is a multistep procedure involving normal tissues, benign disease, LMP or borderline tumor, and malignant tumor.[@b20-cmar-10-3033] We compared malignant ovarian cancer with LMP tumors, benign disease, and normal samples to give more rigorously to the analysis. Second, with 1,217 malignant ovarian cancer patients, 116 LMP, 271 benign patients, and 351 normal samples, the sample size in our study is much larger than that of all previous meta-analyses. Finally, we included the clinicopathological features and prognostic significance of *P16^INK4a^* promoter methylation in ovarian cancer for more comprehensive understanding of the underlying pathogenesis of ovarian cancer. These strengths make our study a useful effort in seeking better understanding of the *P16^INK4a^* promoter methylation in ovarian cancer.

Limitations
===========

Several potential limitations in our current study should be noted. First, the heterogeneity was still large after subgroup analyses in the assessment of the association between *P16^INK4a^* promoter methylation and ovarian cancer risk, which may affect the statistical power. Second, as a retrospective study, a potential unidentified confounding information and selection bias may exist in our meta-analysis. We could not eliminate the possibility of publication bias, where positive results are likely published than negative results. Third, the total sample size was still relatively small for reliably assessing the prognostic value of *P16^INK4a^* promoter methylation in ovarian cancer. Fourth, none of the studies included in our meta-analysis defined the region considered as promoter or provided specific methylation sites. Therefore, we are unable to establish whether or not they focused on the same sequence of *P16^INK4a^* gene. However, the impact of methylation on transcriptional potential depends on the density of the methylated CpG islands and their location relative to the transcription start site. This highlights the importance of a uniform and full-scale reporting of study designs and outcomes. Additionally, previous researches showed that the occurrence of *P16^INK4a^* promoter methylation may depend on the histological subtype.[@b41-cmar-10-3033],[@b48-cmar-10-3033],[@b61-cmar-10-3033] However, we are unable to extract sufficient data to analyze the association between *P16^INK4a^* promoter methylation and high-grade serous carcinomas because no detailed information of *P16^INK4a^* promoter methylation in high-grade serous carcinomas was provided in the eligible articles.

Although with certain limitations, our study is a comprehensive meta-analysis focusing on the correlation of aberrant *P16^INK4a^* promoter methylation with the initiation, development, and prognosis of ovarian cancer to provide a new insight into the pathogenesis of ovarian cancer.

Conclusion
==========

In conclusion, our meta-analysis suggests that aberrant methylation of *P16^INK4a^* promoter may be essential to the initiation of ovarian cancer and in distinguishing malignant from healthy ovarian tissues. Besides, *P16^INK4a^* promoter methylation is a potential predictive factor for poor prognosis in ovarian cancer. This study indicates the need for multicenter large-scale studies to confirm the role of *P16^INK4a^* promoter methylation in ovarian cancer.
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![Forest plots for the association between *P16^INK4a^* methylation and ovarian cancer risk.\
**Notes: (A)** Cancer tissues vs normal tissues; (**B)** cancer tissues vs benign tissues; (**C)** cancer tissues vs LMP tissues.\
**Abbreviations:** LMP, low malignant potential or borderline tumor tissues; M--H, Mantel--Haenszel.](cmar-10-3033Fig2){#f2-cmar-10-3033}

![Forest plots for the association between *P16^INK4a^* methylation and ovarian diseases.\
**Notes: (A)** Benign tissues vs normal tissues; **(B)** LMP tissues vs normal tissues.\
**Abbreviations:** LMP, low malignant potential or borderline tumor tissues; M--H, Mantel--Haenszel.](cmar-10-3033Fig3){#f3-cmar-10-3033}

![Forest plots for the association between *P16^INK4a^* methylation and clinicopathological features in ovarian cancer.\
**Notes: (A)** Age; (**B)** clinical stage; (**C)** tumor grade; (**D)** histological subtype.\
**Abbreviation:** M--H, Mantel--Haenszel.](cmar-10-3033Fig4){#f4-cmar-10-3033}

![Forest plots for *P16^INK4a^* methylation on survival analysis in univariate and multivariate Cox regression model.\
**Notes:** (**A**) PFS in univariate Cox regression model; (**B**) PFS in multivariate Cox regression model; (**C**) OS in univariate Cox regression model; (**D**) OS in multivariate Cox regression model.\
**Abbreviations:** OS, overall survival; PFS, progression-free survival; SE, standard error.](cmar-10-3033Fig5){#f5-cmar-10-3033}

![Sensitivity analyses and Begg's test for publication bias of *P16^INK4a^* methylation during the carcinogenesis of ovarian cancer.\
**Notes: (A** and **D)** Cancer tissues vs normal tissues; (**B** and **E)** sensitivity analysis for the comparison of cancer tissues vs benign tissues; (**C** and **F)** sensitivity analysis for the comparison of cancer tissues vs LMP tissues.\
**Abbreviations:** LMP, low malignant potential or borderline tumor tissues; SE, standard error.](cmar-10-3033Fig6){#f6-cmar-10-3033}

###### 

Characteristics of studies included for the association between *P16^INK4a^* methylation and ovarian cancer risk

  Authors                              Year   Country                                              Geographical location   Sample size[a](#tfn1-cmar-10-3033){ref-type="table-fn"}   Case number   Age (years)[d](#tfn4-cmar-10-3033){ref-type="table-fn"}   Sample type   Method   Methylation site   NOS score                                  
  ------------------------------------ ------ ---------------------------------------------------- ----------------------- --------------------------------------------------------- ------------- --------------------------------------------------------- ------------- -------- ------------------ ----------- ------------------- ---------- ---
  Moselhy et al[@b17-cmar-10-3033]     2015   Saudi Arabia                                         Asia                    Small                                                     14/18         NA                                                        12/32         NA       52.3±12.1          FFPET       MSP                 Promoter   7
  Bhagat et al[@b20-cmar-10-3033]      2014   India                                                Asia                    Large                                                     58/134        5/23                                                      11/26         0/15     49.55±9.72         FFT         qMSP                Promoter   7
  Ozdemir et al[@b24-cmar-10-3033]     2012   Turkey[b](#tfn2-cmar-10-3033){ref-type="table-fn"}   Asia                    Large                                                     1/75          NA                                                        NA            0/75     NA                 Tissue      MS-MLPA             Promoter   7
  Ho et al[@b37-cmar-10-3033]          2012   Taiwan                                               Asia                    Small                                                     1/47          NA                                                        6/29          NA       50(32--66)         FFT         MS-MLPA             Promoter   7
  Cuľbová et al[@b38-cmar-10-3033]     2011   Slovakia                                             Europe                  Small                                                     5/13          0/2                                                       5/19          NA       54.8 (34--74)      FFT         MSP                 Promoter   6
  Abou-Zeid et al[@b22-cmar-10-3033]   2011   Egypt[c](#tfn3-cmar-10-3033){ref-type="table-fn"}    Africa                  Large                                                     21/52         NA                                                        9/43          4/40     60(49--74)         FFT         qMSP                Promoter   7
  Gu et al[@b39-cmar-10-3033]          2009   China                                                Asia                    Large                                                     8/87          NA                                                        13/42         NA       51(21--69)         Tissue      MethyLight          Promoter   7
  Shen et al[@b25-cmar-10-3033]        2008   China                                                Asia                    Large                                                     13/63         NA                                                        NA            0/30     52.8 (33--76)      FFT         MSP                 Promoter   6
  Wu et al[@b40-cmar-10-3033]          2007   Norway                                               Europe                  Large                                                     0/52          0/2                                                       0/2           NA       NA                 FFT         MSP                 Promoter   6
  Tam et al[@b26-cmar-10-3033]         2007   HongKong                                             Asia                    Large                                                     17/89         1/16                                                      1/19          4/16     53.1±1.4           FFT         MSP                 Promoter   7
  Wiley et al[@b42-cmar-10-3033]       2006   Italy                                                Europe                  Large                                                     89/215        4/19                                                      NA            NA       57.7±11.4          FFT         MSP                 Promoter   7
  Li et al[@b27-cmar-10-3033]          2006   China                                                Asia                    Small                                                     6/18          NA                                                        NA            0/10     NA                 Tissue      MSP                 Promoter   5
  Makarla et al[@b29-cmar-10-3033]     2005   USA                                                  America                 Small                                                     7/23          5/23                                                      3/23          0/16     51.5 (20--86)      FFT         MSP                 Promoter   7
  Liu et al[@b28-cmar-10-3033]         2005   USA                                                  America                 Large                                                     13/52         NA                                                        NA            15/40    61.5±9.4           FFT         MSP                 Promoter   5
  Dhillon et al[@b23-cmar-10-3033]     2004   India                                                Asia                    Small                                                     10/25         NA                                                        NA            1/75     NA                 Tissue      MSP                 Promoter   7
  Rathi et al[@b30-cmar-10-3033]       2002   USA                                                  America                 Small                                                     5/49          NA                                                        NA            0/16     56(40--79)         FFT         MSP                 Promoter   7
  Strathdee                            2001   UK                                                   Europe                  Large                                                     0/93          NA                                                        NA            0/18     NA                 FFT         MSP                 Promoter   6
  et al[@b46-cmar-10-3033]                                                                                                                                                                                                                                                                                                                        
  Brown et al[@b45-cmar-10-3033]       2001   UK                                                   Europe                  Small                                                     0/30          0/13                                                      0/14          NA       NA                 FFT         MSP                 Promoter   5
  McCluskey et al[@b47-cmar-10-3033]   1999   USA                                                  America                 Small                                                     21/37         11/15                                                     14/20         NA       NA                 FFT         MSP                 Promoter   6
  Shih et al[@b49-cmar-10-3033]        1997   Australia                                            Oceania                 Small                                                     0/45          0/3                                                       0/2           NA       NA                 Tissue      Southern analysis   Promoter   5

**Notes:**

We defined n\<50 as small size and ≥50 as large size.

Turkey is a transcontinental Eurasian country and is usually assigned to Asia internationally.

Egypt is a transcontinental country spanning the northeast corner of Africa and southwest corner of Asia, usually assigned to Africa internationally.

Age data are presented as mean ± SD or median (IQR).

**Abbreviations:** B, benign tissues; BL, borderline; C, cancer tissues; FFPET, formalin fixed and paraffin embedded tissues; FFT, fast frozen tissues; LMP, low malignant potential or borderline tumor tissues; M, methylated; MS-MLPA, methylation-specific multiplex ligation-dependent probe amplification; MSP, methylation-specific PCR; n, number of patients in the group; NA, not available; NT, normal tissues; NOS, Newcastle Ottawa Scale; qMSP, real-time quantitative MSP.

###### 

Characteristics of studies included for the association between *P16^INK4a^* methylation and clinicopathological features of ovarian cancer

  Authors                                   Year   Country     Geographical location   Number of patients   Age (years)[a](#tfn6-cmar-10-3033){ref-type="table-fn"}   Tumor stage   Tumor grade   Histological subtype                    
  ----------------------------------------- ------ ----------- ----------------------- -------------------- --------------------------------------------------------- ------------- ------------- ---------------------- -------- ------- --------
  Bhagat et al[@b20-cmar-10-3033]           2014   India       Asia                    134                  49.55±9.72                                                19/41         39/93         18/45                  40/89    32/76   26/58
  Cuľbová et al[@b38-cmar-10-3033]          2011   Slovakia    Europe                  13                   54.8 (34--74)                                             NA            NA            NA                     NA       2/6     3/7
  Shen et al[@b25-cmar-10-3033]             2008   China       Asia                    63                   52.8 (33--76)                                             4/22          9/41          6/36                   7/27     7/34    6/29
  Yang et al[@b41-cmar-10-3033]             2006   Hong Kong   Asia                    49                   48.8 (26--79)                                             4/24          5/25          6/22                   3/25     3/17    6/32
  Makarla et al[@b29-cmar-10-3033]          2005   USA         America                 23                   51.5 (20--86)                                             NA            NA            NA                     NA       2/9     5/14
  Liu et al[@b28-cmar-10-3033]              2005   USA         America                 52                   61.5±9.4                                                  NA            NA            10/41                  3/11     NA      NA
  Katsaros et al[@b43-cmar-10-3033]         2004   Italy       Europe                  249                  57(19--82)                                                22/68         68/152        26/75                  64/141   40/86   50/141
  Hashiguchi et al[@b44-cmar-10-3033]       2001   Japan       Asia                    46                   NA                                                        4/21          2/20          7/33                   0/13     2/14    5/32
  McCluskey et al[@b47-cmar-10-3033]        1999   USA         America                 29                   NA                                                        NA            NA            NA                     NA       1/14    1/15
  Milde-Langosch et al[@b48-cmar-10-3033]   1998   Germany     Europe                  44                   NA                                                        NA            NA            NA                     NA       3/11    13/33

**Note:**

Age data are presented as mean ± SD or median (IQR).

**Abbreviations:** M, methylated; n, number of patients in the group; NA, not available.

###### 

Meta-regression and subgroup analyses of *P16^INK4a^* methylation in comparison of cancer tissues vs normal tissues

  Stratified analysis         Number of studies   Pooled OR (95% CI)    Meta-regression       Heterogeneity        
  --------------------------- ------------------- --------------------- --------------------- --------------- ---- --------
  **Publication year**                                                                        0.376                
   ≤2005                      4                   5.69 (0.42--76.14)    2.17 (1.17--4.05)                     84   0.0003
   \>2005                     6                   4.71 (1.30--17.07)    4.65 (2.32--9.30)                     56   0.05
  **Geographical location**                                                                   0.161                
   Asia                       6                   7.85 (1.33--46.32)    5.87 (2.70--12.78)                    70   0.005
   America                    3                   2.31 (0.24--22.01)    1.15 (0.56--2.37)                     68   0.05
   Africa                     1                   6.10 (1.89--19.69)    6.10 (1.89--19.69)                    --   --
  **Method**                                                                                  0.651                
   MSP                        7                   4.49 (0.97--20.64)    2.33 (1.38--3.92)                     77   0.0003
   Others                     3                   6.79 (2.43--18.94)    8.11 (2.93--22.40)                    0    0.57
  **Case sample size**                                                                        0.041                
   \<50                       4                   17.21 (4.54--65.28)   15.75 (4.05--61.34)                   0    0.58
   ≥50                        6                   2.21 (1.33--3.67)     2.74 (0.71--10.53)                    75   0.001

**Abbreviations:** MSP, methylation-specific PCR; OR, odds ratio.

###### 

Methylation of *P16^INK4a^* CpG sites on Illumina HumanMethylation 27 BeadChip from TCGA datasets

  Probe (Illumina HumanMethylation 27)   CpG island location (chromosome: DNA range)   Normal tissue beta value (mean, n=12)   Tumor tissue beta value (mean, n=582)   Adjusted *P*-value[a](#tfn9-cmar-10-3033){ref-type="table-fn"}   Pearson correlation coefficient   Adjusted *P*-value[b](#tfn10-cmar-10-3033){ref-type="table-fn"}
  -------------------------------------- --------------------------------------------- --------------------------------------- --------------------------------------- ---------------------------------------------------------------- --------------------------------- -----------------------------------------------------------------
  cg00718440                             9: 21983444--21986348                         0.016                                   0.016                                   0.960249                                                         0.194104                          0.001719
  cg03079681                             9: 21983444--21986348                         0.015                                   0.026                                   \<0.000001                                                       0.012972                          1.0
  cg07752420                             9: 21958106--21958899                         0.149                                   0.653                                   \<0.000001                                                       0.569887                          \<0.000001
  cg09099744                             9: 21958106--21958899                         0.099                                   0.642                                   \<0.000001                                                       0.630768                          \<0.000001
  cg10895543                             9: 21958106--21958899                         0.120                                   0.651                                   \<0.000001                                                       0.624147                          \<0.000001
  cg11653709                             9: 21958106--21958899                         0.144                                   0.610                                   \<0.000001                                                       0.555400                          \<0.000001
  cg12840719                             9: 21958106--21958899                         0.092                                   0.594                                   \<0.000001                                                       0.627484                          \<0.000001
  cg13479669                             9: 21983444--21986348                         0.045                                   0.027                                   0.004226                                                         --0.150891                        0.0333435
  cg26673943                             9: 21983444--21986348                         0.047                                   0.056                                   0.042428                                                         --0.269361                        \<0.000001

**Notes:**

*P*-value of *t*-test of the difference between normal tissue beta value and tumor tissue beta value.

*P*-value of Pearson's correlation between the tumor tissues beta value and CDKN2A expression (n=368).

**Abbreviation:** TCGA, The Cancer Genome Atlas.

[^1]: These authors contributed equally to this work
